BLUE bluebird bio Inc.

66.78
+0.58  (+1%)
Previous Close 66.2
Open 66
Price To Book 3.32
Market Cap 3,716,447,906
Shares 55,652,110
Volume 1,426,683
Short Ratio
Av. Daily Volume 1,579,513
Stock charts supplied by TradingView

NewsSee all news

  1. bluebird bio Announces Pricing of Public Offering of Common Stock

    bluebird bio, Inc. (NASDAQ:BLUE) today announced the pricing of an underwritten public offering of 9,090,910 shares of its common stock at a public offering price of $55.00 per share, before underwriting discounts. In

  2. bluebird bio Announces Proposed Public Offering of Common Stock

    bluebird bio, Inc. (NASDAQ:BLUE) today announced that it has commenced an underwritten public offering of $400 million of its common stock. bluebird bio also intends to grant the underwriters a 30-day option to purchase

  3. bluebird bio to Present Data from Its Gene and Cell Therapy Programs During the Virtual Edition of the 25th European Hematology Association Annual Congress

    Presentation of new and updated results from ongoing Phase 1/2 HGB-206 study of LentiGlobin for sickle cell disease will include additional patients treated in the study New and updated data, including analysis of

  4. Bristol Myers Squibb and bluebird bio to Present Updated Positive Results from Pivotal KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma Patients at ASCO20

    Ide-cel, an investigational CAR T cell therapy for multiple myeloma, met primary endpoint and key secondary endpoints Pivotal study results demonstrated deep and durable responses in a heavily pre-treated and highly

  5. Bristol Myers Squibb and bluebird bio Provide Regulatory Update on Idecabtagene Vicleucel (ide-cel, bb2121) for the Treatment of Patients with Multiple Myeloma

    Bristol Myers Squibb to host an investor call today at 8:00 a.m. EDT bluebird bio to host an investor call today at 8:45 a.m. EDT Bristol Myers Squibb (NYSE:BMY) and bluebird bio, Inc. (NASDAQ:BLUE) today announced

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial to be initiated 1H 2020.
LentiGlobin - HGB-210
Sickle Cell Disease (SCD)
Phase 3 updated data due at EHA June 11-14, 2020
LentiGlobin - HGB-212 Northstar-3 (EHA)
TDT and the β0/β0genotype
Refusal-to-file letter received May 13, 2020. BLA to be refiled no later than July 2020.
ide-cel bb2121 - KarMMa
Relapsed/refractory multiple myeloma
Phase 3 updated data due at EHA June 11-14, 2020.
LentiGlobin - HGB-207 Northstar-2 (EHA)
non-β0/β0 transfusion-dependent thalassemia (TDT)
Phase 2/3 updated data due by the end of 2020.
Lenti-D - Starbeam
Childhood cerebral adrenoleukodystrophy (CCALD)
BLA filing to be completed mid-2021.
LentiGlobin
β-Thalassemia
Phase 1/2 updated data due at EHA June 11-14, 2020.
LentiGlobin - HGB-206 (EHA)
Sickle disease
Phase 1 data at ASH December 9, 2019 - 83% complete response.
bb21217
Multiple Myeloma
Phase 3 trial to be initiated 2020.
LentiGlobin - HGB-211
Sickle Cell Disease (SCD)

Latest News

  1. bluebird bio Announces Pricing of Public Offering of Common Stock

    bluebird bio, Inc. (NASDAQ:BLUE) today announced the pricing of an underwritten public offering of 9,090,910 shares of its common stock at a public offering price of $55.00 per share, before underwriting discounts. In

  2. bluebird bio Announces Proposed Public Offering of Common Stock

    bluebird bio, Inc. (NASDAQ:BLUE) today announced that it has commenced an underwritten public offering of $400 million of its common stock. bluebird bio also intends to grant the underwriters a 30-day option to purchase

  3. bluebird bio to Present Data from Its Gene and Cell Therapy Programs During the Virtual Edition of the 25th European Hematology Association Annual Congress

    Presentation of new and updated results from ongoing Phase 1/2 HGB-206 study of LentiGlobin for sickle cell disease will include additional patients treated in the study New and updated data, including analysis of

  4. Bristol Myers Squibb and bluebird bio to Present Updated Positive Results from Pivotal KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma Patients at ASCO20

    Ide-cel, an investigational CAR T cell therapy for multiple myeloma, met primary endpoint and key secondary endpoints Pivotal study results demonstrated deep and durable responses in a heavily pre-treated and highly

  5. Bristol Myers Squibb and bluebird bio Provide Regulatory Update on Idecabtagene Vicleucel (ide-cel, bb2121) for the Treatment of Patients with Multiple Myeloma

    Bristol Myers Squibb to host an investor call today at 8:00 a.m. EDT bluebird bio to host an investor call today at 8:45 a.m. EDT Bristol Myers Squibb (NYSE:BMY) and bluebird bio, Inc. (NASDAQ:BLUE) today announced

  6. bluebird bio Announces Amended BCMA CAR-T Collaboration Agreement

    - Bristol Myers Squibb to buy out its ex-U.S. milestone and royalty obligations to bluebird bio for $200 million – - Bristol Myers Squibb assumes responsibility for vector manufacturing in ex-US territories – -

  7. Hitachi Chemical Advanced Therapeutics Solutions and apceth Biopharma GmbH Enter into Strategic Clinical and Commercial Manufacturing Agreements with bluebird bio

    Hitachi Chemical Advanced Therapeutics Solutions, LLC (HCATS) and apceth Biopharma GmbH (apceth), both subsidiaries of Hitachi Chemical Co., Ltd. (Hitachi Chemical) today announced that they have expanded their

  8. bluebird bio Provides Operational and Business Update and Reports First Quarter 2020 Financial Results

    - Alignment with FDA on an accelerated regulatory path for LentiGlobin for sickle cell disease based on HGB-206 study with targeted submission in 2H 2021 - - Completed submission with Bristol Myers Squibb of Biologics

  9. bluebird bio to Present Updated Results From Pivotal Phase 2 KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma During ASCO20 Virtual Scientific Program

    -Virtual oral presentation will include updated efficacy and safety data from pivotal Phase 2 KarMMa study of ide-cel- -Biologics License Application under review with U.S. Food and Drug Administration

  10. bluebird bio Announces First Quarter 2020 Earnings Conference Call and May Investor Event

    bluebird bio, Inc. (NASDAQ:BLUE) today announced it will hold a conference call to discuss first quarter 2020 financial results and business updates on Monday, May 11 at 8:00 am ET. Investors may listen to the call on

  11. Bristol Myers Squibb and bluebird bio Announce Submission of Biologics License Application (BLA) for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121) to FDA

    BLA submission includes results from pivotal Phase 2 KarMMa study evaluating ide-cel in a heavily pre-treated patient population with relapsed and refractory multiple myeloma Bristol Myers Squibb (NYSE:BMY) and

  12. bluebird bio Provides Assessment of Impact of COVID-19, Update on Business Operations and Clinical Program Development

    - Company to hold investor conference call today, March 26, 2020 at 8:30 am ET – bluebird bio, Inc. (NASDAQ:BLUE) today provided an update in response to the global COVID-19 pandemic. The company has taken steps to

  13. bluebird bio Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Operational Progress

    - First conditional approval of ZYNTEGLOTM (autologous CD34+ cells encoding βA-T87Q-globin gene) gene therapy for patients 12 years and older with transfusion-dependent β-thalassemia who do not have β0/β0 genotype in

  14. bluebird bio Announces Upcoming Investor Events

    bluebird bio, Inc. (NASDAQ:BLUE) today announced that members of the management team will present at the following upcoming investor conferences: 9th Annual SVB Leerink Global Healthcare Conference, Wednesday,

  15. bluebird bio Announces Launch in Germany of ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene) Gene Therapy for Patients 12 Years and Older with Transfusion-Dependent β-Thalassemia Who Do Not Have β0/β0 Genotype

    First agreements with statutory health insurances utilize bluebird's innovative value-based payment model and provide coverage for ZYNTEGLO for up to 50% of patients in Germany First qualified treatment center

  16. bluebird bio Announces Investor Events in January

    bluebird bio, Inc. (NASDAQ:BLUE) today announced that members of the management team will present at the following upcoming investor conferences in January: Goldman Sachs 12th Annual Healthcare CEOs Unscripted: A

  17. bluebird bio and Bristol-Myers Squibb Present Updated Data from Ongoing Phase 1 Study of BCMA-Targeted CAR T Cell Therapy bb21217 in Relapsed/Refractory Multiple Myeloma at 61st ASH Annual Meeting and Exposition

    Safety profile consistent with known toxicities of CAR T therapies CAR T persistence observed in 8/10 evaluable responders at Month 6 and 2/2 evaluable responders at Month 18 bluebird bio, Inc. (NASDAQ:BLUE) and

  18. bluebird bio Presents New Data Demonstrating Long-Term Transfusion Independence and Safety for LentiGlobin™ Gene Therapy for β-thalassemia (betibeglogene autotemcel) at 61st ASH Annual Meeting and Exposition

    More than four years of durable transfusion independence (TI), stable total hemoglobin (Hb) levels and reduced liver iron concentrations in completed Phase 1/2 Northstar (HGB-204) study in patients who do not have a

  19. bluebird bio Presents New Data from Ongoing Phase 1/2 HGB-206 Study of LentiGlobin™ Gene Therapy for Sickle Cell Disease (SCD) at 61st ASH Annual Meeting and Exposition

    99% reduction in annualized rate of vaso-occlusive crises (VOC) and acute chest syndrome (ACS) in Group C patients with history of VOCs and ACS who had at least six months follow-up, no reports of ACS or serious VOCs at

  20. Bristol-Myers Squibb and bluebird bio Announce Positive Top-line Results from the Pivotal Phase 2 KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma

    Study met its primary endpoint and key secondary endpoint, demonstrating deep and durable responses in a heavily pre-treated multiple myeloma patient population Safety results are consistent with the data presented

  21. bluebird bio Announces Live Webcast to Review Clinical Data Presented at the American Society of Hematology (ASH) Annual Meeting

    bluebird bio, Inc. (NASDAQ:BLUE) today announced that the company will host a live webcast on December 9, 2019 at 8:00 p.m. ET to review clinical data presented at the 61st American Society of Hematology Annual Meeting

  22. bluebird bio and Forty Seven Announce a Research Collaboration to Study an All Antibody Conditioning Regimen for Use in Combination with Autologous Lentiviral Vector Hematopoietic Stem Cell Gene Therapy

    bluebird bio, Inc. (NASDAQ:BLUE) and Forty Seven, Inc. (NASDAQ:FTSV) announced today that they have entered into a research collaboration to pursue clinical proof-of-concept for Forty Seven's novel antibody-based

  23. bluebird bio to Present New Data from Gene and Cell Therapy Programs at 61st American Society of Hematology Annual Meeting and Exposition

    Updated safety and efficacy results from ongoing Phase 1 CRB-402 study of bb21217 in relapsed/refractory multiple myeloma Updated results from ongoing Phase 1/2 (HGB-206) study of LentiGlobin™ gene therapy for

  24. bluebird bio Reports Third Quarter 2019 Financial Results and Highlights Operational Progress

    - Continued progress towards 2022 vision of four marketed gene and cell therapy products with robust development pipeline - - ZYNTEGLO commercial launch advancing with European Medicines Agency approval of refined

  25. bluebird bio Announces Transition of Chief Strategy Officer Jeffrey T. Walsh

    bluebird bio, Inc. (NASDAQ:BLUE) today announced that Jeffrey T. Walsh, chief strategy officer, has decided to transition from his current role effective January 6, 2020. "On behalf of bluebird, we are grateful for

  26. European Medicines Agency Approves Refined Commercial Manufacturing Specifications for ZYNTEGLO™

    First gene therapy for patients 12 years and older with transfusion-dependent β-thalassemia who do not have a β0/β0 genotype now available to be manufactured in the European Union bluebird bio, Inc. (NASDAQ:BLUE)

  27. bluebird bio and Novo Nordisk Enter into Research Agreement to Develop in vivo Genome Editing Candidates for Haemophilia and Other Severe Genetic Diseases

    bluebird bio, Inc. (NASDAQ:BLUE) and Novo Nordisk A/S (NVO) today announced that they have entered into a research collaboration to jointly develop next-generation in vivo genome editing treatments for genetic diseases,

  28. bluebird bio Appoints William R. Sellers, M.D. to Board of Directors

    bluebird bio, Inc. (NASDAQ:BLUE) today announced that it has appointed William R. Sellers, M.D. to its Board of Directors. "I'm excited to welcome Bill to the Board to help navigate an important stage in bluebird's

  29. bluebird bio Presents Updated Data from Phase 2/3 Clinical Study of Lenti-D™ Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) at the 13th European Pediatric Neurology Society (EPNS) Congress

    Long-Term Follow-up Data Show That the 88% of Patients Treated in the Starbeam Study (ALD-102) Were Free of Major Functional Disabilities (MFDs) at Two Years, and Continued to Remain MFD-Free at up to Five Years of

  30. bluebird bio to Present Data from Clinical Development Program of Lenti-DTM Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) at the 13th European Pediatric Neurology Society (EPNS) Congress

    Data Include Updates from Phase 2/3 Starbeam Study (ALD-102) of Lenti-D for CALD and Ongoing Observational Study (ALD-103) of Allogeneic Hematopoietic Stem Cell Transplant for CALD bluebird bio, Inc. (NASDAQ:BLUE)

  31. bluebird bio Announces Investor Events in September

    bluebird bio, Inc. (NASDAQ:BLUE) today announced that members of the management team will present at the following upcoming investor conferences in September: Citi 14th Annual Biotech Conference, Wednesday, September